ANZ0001 {ordinalCont}

ANZ0001 trial

Description

The complete ANZ0001 trial data set

Usage

data(ANZ0001)

Format

A data frame with 2473 rows and 11 variables

Details

The ANZ0001 trial, conducted by the ANZ Breast Cancer Trials Group, is an unblinded, multi-centre, randomized trial with three chemotherapy treatment arms, concluded in 2005 (Stockler et al 2007). Health-related quality of life measures (Overall quality of life, Physical Well-Being, Mood, Pain, Nausea and Vomiting, Appetite) are assessed at each chemotherapy treatment cycle, from randomization until disease progression, when treatment is interrupted. The treatments Intermittent Capecitabine (IC) and Continuous Capecitabine (CC) are compared with the standard combination treatment CMF, each with its own protocol. There is no maximum duration of treatment, but it is interrupted on disease progression, or when patient intolerance or unacceptable toxicity are recorded. The data set is extracted from the ANZ0001 trial and contains information from 292 patients with complete quality of life measurements.

The variables are as follows:

randno	patient ID number
cycleno	chemotherapy cycle number
age	age of patient at entry to study
bsa	Body Surface Area (m^2)
treatment	treatment received by patient (1,2,3)
overall	Overall quality of life as recorded by the patient on a LASA scale, normalized to (0, 1)
phys	Physical Well-Being as recorded by the patient on a LASA scale, normalized to (0, 1)
mood	Mood as recorded by the patient on a LASA scale, normalized to (0, 1)
pain	Pain as recorded by the patient on a LASA scale, normalized to (0, 1)
nausvom	Nausea and Vomiting as recorded by the patient on a LASA scale, normalized to (0, 1)
appetite	Appetite as recorded by the patient on a LASA scale, normalized to (0, 1)

References

Stockler, M., T. Sourjina, P. Grimison, V. Gebski, M. Byrne, V. Harvey, P. Francis et al. “A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC).” In ASCO Annual Meeting Proceedings, vol. 25, no. 18_suppl, p. 1031. 2007.